Macular Atrophy Affecting Visual Outcomes in Patients Undergoing Anti-VEGF Treatment in Routine Clinical Practice

Autor: Amy Babiuch, Weilin Song, Grace J Tsai, Ang Li, Grant L Hom, Rishi P Singh, Felipe F Conti, Nathaniel B. Rieveschl, Thais F. Conti
Rok vydání: 2019
Předmět:
Male
Vascular Endothelial Growth Factor A
medicine.medical_specialty
Visual acuity
genetic structures
Recombinant Fusion Proteins
Visual Acuity
Angiogenesis Inhibitors
03 medical and health sciences
0302 clinical medicine
Atrophy
Foveal
Ophthalmology
Ranibizumab
medicine
Humans
Macula Lutea
Fluorescein Angiography
Aged
Retrospective Studies
medicine.diagnostic_test
business.industry
Case-control study
Retrospective cohort study
Macular degeneration
Middle Aged
Fluorescein angiography
medicine.disease
eye diseases
Confidence interval
Choroidal Neovascularization
Bevacizumab
Receptors
Vascular Endothelial Growth Factor
Case-Control Studies
Intravitreal Injections
030221 ophthalmology & optometry
Wet Macular Degeneration
Female
sense organs
medicine.symptom
business
Tomography
Optical Coherence
Zdroj: Ophthalmic surgery, lasersimaging retina. 51(2)
ISSN: 2325-8179
Popis: BACKGROUND AND OBJECTIVE: To explore how baseline macular atrophy (MA) affects visual acuity (VA) in patients receiving intravitreal anti-vascular endothelial growth factor (VEGF) injections for neovascular age-related macular degeneration (nAMD). PATIENTS AND METHODS: A retrospective, case control series. Patients were grouped into three cohorts based on baseline spectral-domain optical coherence tomography image findings: foveal MA, nonfoveal MA, and no MA. Outcomes were assessed at 1, 2, and 3 years following anti-VEGF therapy. RESULTS: No differences existed in MA growth between eyes with foveal and nonfoveal MA (0.89 mm 2 [95% confidence interval (CI), 0.64–1.14] vs. 0.88 mm 2 [95% CI, 0.72–1.05]) after adjusting for baseline lesion sizes at 3 years. Foveal MA patients lost an average of 19.4 ETDRS letters (95% CI, −30.8 to −8.0) after 3 years. Nonfoveal MA patients gained an average of 1.1 ETDRS letters (95% CI, −6.8 to 9.0), and patients without MA averaged a gain of 9.7 ETDRS letters (95% CI, 5.5–14.0). CONCLUSION: In patients with nAMD receiving anti-VEGF in routine clinical practice, presence of baseline foveal MA was associated with significant vision loss. [ Ophthalmic Surg Lasers Imaging Retina. 2020;51:68–75.]
Databáze: OpenAIRE
Externí odkaz: